Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Recruiting now · Phase 1

Conditions studied: Advanced Cancer

In brief

This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers

Key facts

Study ID

NCT06188624

Run by

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

People needed

150

Starts

2024-02-01

Expected to finish

2027-12-01

Last updated by the study team

2025-04-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects voluntarily join this study, sign the informed consent form, and have good compliance；
• Age: 18-75 years; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months；
• Histologically or cytologically diagnosed with advanced cancers;
• Subjects with advanced malignancies who have failed standard therapy or lack effective treatment;
• Major organs are functioning well;
• Female and male subjects of childbearing potential should agree to practice contraception during the study and until 6 months after the completion of the study.

You may not qualify if…

• Current concomitant or ever presented with other malignancies within 2 years prior to the first dose;
• Unresolved toxicity of Grade 1 or above according to CTCAE due to any prior anti-tumor therapy;
• Significant surgical treatment, biopsy, or significant traumatic injury within 28 days prior to the first dose;
• Long-term unhealed wounds or fractures
• Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose;
• A history of psychotropic drug abuse and cannot be abstained, or have a mental disorder;
• Subjects with any severe and/or uncontrolled disease;
• History of live attenuated vaccination within 2 weeks prior to the first dose or planned live attenuated vaccination during the study;
• Previous history of unexplained severe allergies, hypersensitivity to monoclonal antibodies or exogenous human immunoglobulins, or hypersensitivity to TQB2922 for injection or its excipients;
• According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the patients or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.

Where it is running

• Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (enrolling)
• The first affiliated hospital of Guangzhou medical university — Guangzhou, Guangdong, China
• Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
• Henan Cancer Hospital — Zhengzhou, Henan, China
• Henan Provincine People's Hospital — Zhengzhou, Henan, China
• The First Affiliated Hospital of Zhengzhou University — Zhengzhou, Henan, China
• The Second Xiangya Hospital of Central South University — Changsha, Hunan, China
• Hunan Cancer Hospital — Changsha, Hunan, China
• Nanjing Drum Tower Hospital — Nanjing, Jiangsu, China
• Affiliated Zhongshan Hospital of Dalian University — Dalian, Liaoming, China
• Department of Medical Oncology, The First Hospital of China Medical University — Shenyang, Liaoning, China
• The First Affiliated Hospital of Xi'an Jiaotong University — Xi'an, Shaanxi, China
• Shanghai Pulmonary Hospital — Shanghai, Shanghai Municipality, China
• Affiliated Hospital of North Sichuan Medical College — Nanchong, Sichuan, China
• Tianjin Medical University Cancer Institute and Hospital — Tianjin, Tianjin Municipality, China
• Chongqing University Cancer Hospital — Chongqing, Chongqing Municipality, China
• Yunnan Cancer Hospital — Kunming, Yunnan, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.